BiotechTube
MyoGene Bio

MyoGene Bio

Cambridge, United States· Est.
myogenebio.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $2.5M

Overview

MyoGene Bio is a private, pre-clinical stage biotech developing gene editing therapies for muscular disorders, with an initial focus on Duchenne muscular dystrophy (DMD). Its lead candidate, MyoDys45-55, is designed as a single-treatment platform targeting the underlying genetic mutation in approximately 50% of DMD patients. The company has secured initial funding and key regulatory designations, building on foundational research from its UCLA-affiliated scientific founders. MyoGene Bio operates in the high-need, high-value rare disease therapeutics space.

Muscular DisordersRare Disease

Technology Platform

Proprietary gene editing platform designed for permanent correction of genetic mutations causing muscular dystrophies, initially targeting exon 45-55 region of the dystrophin gene for Duchenne.

Funding History

1
Total raised:$2.5M
Seed$2.5M

Opportunities

The lead program targets ~50% of the Duchenne patient population, representing a large addressable market with high unmet need.
Orphan Drug and Rare Pediatric Disease designations provide regulatory and potential financial benefits (e.g., priority review voucher).
The platform technology could be expanded to other mutations and muscle diseases.

Risk Factors

The company is in early pre-clinical stage with very limited capital ($1.42M), requiring significant future financing.
Gene editing faces major technical hurdles including delivery, efficiency, and safety.
The DMD competitive landscape is advanced, with several therapies already approved or in late-stage trials.

Competitive Landscape

The DMD treatment space is highly competitive, featuring approved exon-skipping drugs (Sarepta, NS Pharma), a recently approved gene therapy (Elevidys from Sarepta/Roche), and numerous other genetic approaches in development. MyoGene Bio's differentiation is its focus on a permanent gene editing fix for a broad patient subset, but it trails behind companies with commercial products and later-stage pipelines.

More companies in Rare & Orphan Diseases →More companies in United States →